Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/37023

Title:	Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
Authors:	Novello, S Mazières, J Oh, I-J de Castro, J Migliorino, M R Helland, Å Dziadziuszko, R Griesinger, F Kotb, A Zeaiter, A Cardona, A Balas, B Johannsdottir, H K Das-Gupta, A Wolf, J View more
Issue Date:	1-Jun-2018
Citation:	Ann. Oncol..2018 Jun;(29)6:1409-1416
Abstract:	This is the first trial to directly compare efficacy and safety of alectinib versus standard chemotherapy in advanced/metastatic anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) patients who have progressed on, or were intolerant to, crizotinib.
PMID:	29668860
URI:	https://hdl.handle.net/20.500.12530/37023
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos Hospitales > H. U. La Paz > Artículos

Files in This Item:

File	Description	Size	Format
PMC6005013.pdf		610.72 kB	Adobe PDF	View/Open